UNCY

Unicycive Therapeutics, Inc. [UNCY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

UNCY Stock Summary

Top 10 Correlated Stocks

UNCY

In the News

UNCY Financial details

Company Rating
-
Market Cap
42.4M
Income
-41.19M
Revenue
675K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.84
Forward P/E
-
PEG
-0.1
P/S
51.49
P/B
9.5
P/C
-
P/FCF
-1.74
Quick Ratio
0.93
Current Ratio
1.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.25
EPS next Y
-
EPS next Q
-
EPS this Y
3.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
69.23%
-
-
-
-
SMA20
-9.38%
SMA50
-17.14%
SMA100
38.1%
Inst Own
-
Inst Trans
-
ROA
-199%
ROE
-763%
ROC
-4.96%
Gross Margin
100%
Oper. Margin
-2931%
Profit Margin
-5737%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.47-1.9
52W High
-
52W Low
-
RSI
51.79
Rel Volume
3.98
Avg Volume
347.11K
Volume
1.38M
Perf Week
16.11%
Perf Month
-20.69%
Perf Quarter
84.98%
Perf Half Y
64.07%
-
-
-
-
Beta
2.648
-
-
Volatility
0.03%, 0.05%
Prev Close
1.15%
Price
0.6169
Change
2.36%

Something similar

Top by Market Cap
NVD.DE
M&M.NS
FB2A.DE
V
EMBASSY.NS
Same Sector
234080.KS
ANGO
IMGN
RPID
C6O.DE
Top Correlated Stocks
VECO
ELEV
SKYT
Similar Market Cap
MFOMX
0HTC.L
SOHOO
BNN.DE
BANI.BR

Company Profile

Healthcare Biotechnology
  • Volume Average 347.11K
  • Market Capitalization 42.4M
  • Employee 14
  • CEO Dr. Shalabh K. Gupta M.D., MPA
  • Headquarters Los Altos,CA,US
  • IPO Date 2021-07-12
  • Website https://www.unicycive.com

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.